key: cord-0766291-itj2g41i authors: González, Francisco J.; Miranda, Fabián A.; Chávez, Sebastián M.; Gajardo, Abraham I.; Hernández, Ariane R.; Guiñez, Dannette V.; Díaz, Gonzalo A.; Sarmiento, Natalia V.; Ihl, Fernando E.; Cerda, María A.; Valencia, Camila S.; Cornejo, Rodrigo A. title: Clinical characteristics and in‐hospital mortality of patients with COVID‐19 in Chile: A prospective cohort study date: 2021-10-05 journal: Int J Clin Pract DOI: 10.1111/ijcp.14919 sha: 87ae5da7f9c3fd8407c48bf756dbe73fc56e5de7 doc_id: 766291 cord_uid: itj2g41i AIMS OF THIS STUDY: To describe the Latin American population affected by COVID‐19, and to determine relevant risk factors for in‐hospital mortality. METHODS: We prospectively registered relevant clinical, laboratory, and radiological data of adult patients with COVID‐19, admitted within the first 100 days of the pandemic from a single teaching hospital in Santiago, Chile. The primary outcome was in‐hospital mortality. Secondary outcomes included the need for respiratory support and pharmacological treatment, among others. We combined the chronic disease burden and the severity of illness at admission with predefined clinically relevant risk factors. Cox regression models were used to identify risk factors for in‐hospital mortality. RESULTS: We enrolled 395 adult patients, their median age was 61 years; 62.8% of patients were male and 40.1% had a Modified Charlson Comorbidity Index (MCCI) ≥5. Their median Sequential Organ Failure Assessment (SOFA) score was 3; 34.9% used a high‐flow nasal cannula and 17.5% required invasive mechanical ventilation. The in‐hospital mortality rate was 14.7%. In the multivariate analysis, were significant risk factors for in‐hospital mortality: MCCI ≥5 (HR 4.39, P < .001), PaO(2)/FiO(2) ratio ≤200 (HR 1.92, P = .037), and advanced chronic respiratory disease (HR 3.24, P = .001); pre‐specified combinations of these risk factors in four categories was associated with the outcome in a graded manner. CONCLUSIONS AND CLINICAL IMPLICATIONS: The relationship between multiple prognostic factors has been scarcely reported in Latin American patients with COVID‐19. By combining different clinically relevant risk factors, we can identify COVID‐19 patients with high‐, medium‐ and low‐risk of in‐hospital mortality. The epidemiological aspects, clinical characteristics, risk factors, and outcomes of COVID-19 have mostly been reported in China, Europe, and the United States. [1] [2] [3] [4] In relation to this, most of the patients in the reports are men with a median age close to 60 years of age and suffer more than one comorbidity; mainly hypertension, obesity and diabetes. Clinical findings most frequently observed are the respiratory features, but extrapulmonary manifestations are also documented, 5, 6 such as coagulopathy, acute kidney injury (AKI), and myocardial injury, amongst others, which can be explained by the direct action of SARS-CoV2 infection on the endothelium. 5 Older age, the severity of the disease and elevation of biomarkers such as D-dimer on admission increase the lethality rate, 1-4 especially those requiring mechanical ventilation, with a mortality rate of 40.5% (95% CI 31.2:40.6). 7 Latin America is one of the most affected regions, presenting one of the highest mortality rate globally, being highest in South America with 9.2% case fatality ratio. 8 This excess of mortality has been associated with precarious health services, economic instability, informal jobs and a social inequity that deepened in the health crisis. 9 However, there is a severe lack of data from this region despite being more affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than other ethnicities. 10 Chile was one of the last countries to be affected by the disease in Latin America. Nevertheless, it experienced rapid transmission and unrelenting spread, with >16 000 cases per million inhabitants, making it the most affected country in Latin America and the fourth worldwide. 11 From a clinical viewpoint, combining different risk factors, such as disease burden, with SARS-CoV-2 severity might improve our understanding of patients' findings and facilitate clinicians' decision making to deliver the most appropriate care. We analysed a Latin American cohort of Chilean patients with COVID-19 who were hospitalised during the first 100 days of the pandemic, focusing on their risk of in-hospital mortality, and examined the risk factors associated with SARS-CoV-2 infection upon admission. This was a prospective cohort study of adult inpatients at a University of Chile Clinical Hospital. We enrolled all patients aged >18 years who were diagnosed with COVID-19 and were admitted to the emergency department from 1 March to 11 June 2020, through prospective identification using daily admission records. To our knowledge, we present one of the first prospective cohort studies in Latin America. In-hospital mortality risk was similar compared with other cohorts SARS-CoV-2 infection was confirmed using RT-PCR of nasopharyngeal swabs. All laboratory procedures were performed at the discretion of the treating physician, who was encouraged to follow local clinical guidelines. FilmArray of nasopharyngeal swabs, and urinary antigen (pneumococcal/Legionella) tests and blood cultures were performed for viral and bacterial co-infection assessment, respectively. Chest CT was performed and classified as COVID-19unrelated, typical/atypical pattern, and unspecified, as previously suggested. 15 Comorbidities and age were summarised using the MCCI (≥5 was considered "high comorbidity"). 16 Functional dependency was defined by a Barthel score <60 in patients aged 65 years or older. Acute >3 seconds or skin mottling score >0). 22 Definitions for AKI, deep vein thrombosis, pulmonary embolism, among others, are listed in Supporting Information. In addition to the known scores, mortality risk was categorised based on a clinical perspective that contemplates chronic disease burden and the severity of acute illness. For these purposes, we combined specific known risk factors, such as comorbidities. MCCI is a validated prognosis tool in elder patients, which measures the burden of chronic diseases. 16 A high chronic disease burden (chronic ⊕) was defined as an MCCI score ≥5. 16 Considering that the lung pa- The primary outcome was in-hospital mortality. Secondary outcomes were the use of IMV and high-flow nasal cannula (HFNC), awake and ventilated prone positioning, septic shock, AKI, renal replacement therapy, thromboembolic disease, and co-infections. The duration and timing of IMV and HFNC were also assessed. Patients were discharged when clinical remission of respiratory symptoms, absence of fever, and suspension of supplemental oxygen for ≥24 hours was achieved. Patients were followed up until death, hospital discharge, or 10 July 2020 (to ensure ≥28 days of follow-up), whichever came first. The Mann-Whitney U test or Fisher's exact test was used to compare baseline characteristics and secondary outcomes between survivors and non-survivors. Cox regression models were used to identify risk factors for in-hospital mortality among baseline characteristics, excluding symptoms. Time was considered as days to the event. Hospital admission and the proportional hazard assumption for each model were tested using Schoenfeld residuals. Univariate hazard ratios (HR) and 95% confidence intervals (95% CI) were presented for variables that showed strong evidence against the null hypothesis (P < .05). Variables considered in the multivariate analysis were selected depending on available background and full data. In the final model, we included variables related to the chronic disease burden (MCCI and advanced chronic respiratory disease (ACRD)), and others related to acute illness (PaO 2 /FiO 2 ratio ≤200 and abnormal perfusion), together with hypertension (a widely reported risk factor not included in the MCCI). Finally, we constructed Kaplan-Meier curves and unadjusted Cox models to explore different combined risk factors. Missing data were not imputed and available cases analysis was performed for incomplete data (Supporting Information). All statistical analyses were performed using Stata (version 12.0; StataCorp LLC) (Supporting Information). Overall, 395 patients were enrolled. Those who remained hospitalised were followed up for ≥28 days; 97.7% of whom had confirmed Symptoms that developed before hospital admission and clinical presentation at the emergency department are listed in Table 2 . The most common symptoms were dyspnoea (84.6%), myalgia (77.5%), cough (76.2%), and fever (60.5%). The median time from symptom onset to emergency department consultation was 7 days (IQR, 5-10). The median SOFA, qSOFA, and CURB-65 scores were 3, 1, and 1, respectively. Laboratory and radiological findings at hospital admission are summarised in Table 3 . Over 75% of patients had an inflammatory response, hypoxia, and hypocapnia. FilmArray Respiratory Panel was performed in 84.6% of patients; seven had viral co-infections. One patient had a positive result for pneumococcal urinary antigen. Chest CT was performed in 379 patients: 344 (90.8%) had a typical pattern. All patients required oxygen. Two hundred and thirty-seven (60.0%) were supported using only low-flow oxygen devices. HFNC was The non-survivors were older, had a higher disease burden (especially advanced lung disease), were less symptomatic, and consulted the emergency department, on average, 24 hours before the survivors. They presented with greater abnormalities in vital signs and had a greater inflammatory response, hypoxemia, and alteration of gas exchange (PaO 2 /FiO 2 ratio) than the survivors (Table 3) . Additionally, the non-survivors presented with greater lymphopenia and elevated lactate dehydrogenase/D-dimer levels. There were no differences in the CT patterns between the survivors and non-survivors (P = .09). The non-survivors required ventilatory support, heparin, and corticosteroids more often than the survivors. During the follow-up, 36 patients (10.7%) were diagnosed with thromboembolic disease (pulmonary embolism, N = 32), without significant differences between the survivors and non-survivors (10.7% vs 12.1%, P = .82). AKI and septic shock were more common in the non-survivors than in survivors (53.2% vs 14.5% and 41.4% vs 8.9%, respectively; P < .001) ( Table 4 ). Differences in pharmacological therapies are shown in Supporting Information. The length of hospital stay was 9 days (IQR, 5-17) for the survivors and 11 days (IQR, 5-16) for non-survivors (P = .523). At the end of the study, 24 patients (6.1%) remained hospitalised with a median length of 35-day stay (IQR, 27-41). In the multivariate analysis, an MCCI ≥5, PaO 2 /FiO 2 ratio ≤200, abnormal perfusion, and advanced CRD were independent risk factors for in-hospital mortality (P < .05; Table 5 This is the first prospective Latin American cohort study on COVID-19 inpatients. Despite higher severity scores than those reported previously, the mortality rate of 14.6% was comparable to that in other The baseline characteristics of the patients in our cohort, time from symptom onset to hospitalisation, frequency of symptoms, and laboratory findings were similar to those reported previously. 2 Fever was present only in 31.6% of non-survivors ( Abbreviations: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; CK, creatine kinase; COVID-19, coronavirus disease 2019; ESR, erythrocyte sedimentation rate; INR, international normalised ratio; IQR, interquartile range; LDH, lactate dehydrogenase; paCO 2, partial pressure of carbon dioxide; paO 2, partial pressure of oxygen; paO 2 /FiO 2 ratio of arterial oxygen partial pressure to the fraction of inspired oxygen. despite the higher severity. Therefore, the lower-than-expected rate of IMV and the high use of HFNC are in line with the findings of Zucman et al, 26 who suggested that HFNC might reduce the need for IMV in up to one-third of patients. 27 The role of HFNC in avoiding progression to IMV, with or without awake prone positioning and prolonged ventilated prone positioning, needs to be addressed in future research. Few pharmacological therapies were used in this cohort. Hydroxychloroquine was infrequently indicated; prior to the RECOVERY trial, 28 corticosteroids were mainly indicated for reasons other than COVID-19. Tocilizumab, immunoglobulin, and antivirals were not used. Conversely, antibiotics and thromboprophylaxis were frequently indicated. Current evidence supports our general approach to pharmacological therapies. 27 Regarding secondary outcomes, co-infection occurred infrequently, as reported previously. 25 AKI, experienced by 20.5% of patients, was as frequent as that reported in a study on severe COVID-19 patients. 29 Thromboembolic disease was diagnosed in 10.8% of patients. Few patients were empirically anticoagulated because of the high risk of venous thromboembolism. The latter is in agreement with the current recommendations of the American Society of Hematology, which discourages empiric anticoagulation in critically ill COVID-19 patients. 30 We identified several risk factors related to in-hospital mortality. As described previously, 1 older age and comorbidities (hypertension, cancer, chronic kidney disease, stroke, dementia, rheumatological disease, and advanced CRD) were significant risk factors. Nevertheless, our data could be underpowered to detect an association with other important comorbidities (such as diabetes, asthma, chronic liver disease and COPD, among others). The MCCI, which groups age and several comorbidities, 31 exhibited the strongest association with mortality when analysing disease burden. Despite being clinically significant, data on COVID-19 that evaluate comorbidities based on validated indices as risk factors are limited. Advanced CRD other than COPD are not included in the MCCI, which showed a strong association with mortality. The risk factors that accounted for illness severity on admission were similar to those described previously. In this large prospective cohort of Latin American COVID-19 patients, we observed a similar mortality rate as reported in other regions, even though our patients had more severe disease. Increased use of a highly coordinated, systematic management approach and decreased use of experimental therapies could affect mortality risk. Independent risk factors associated with in-hospital mortality included the MCCI, advanced CRD, a low PaO 2 /FiO 2 ratio and abnormal perfusion at admission. These associations were greatly enhanced when taken as groups, which, in turn, has better clinical applicability. Risk factors and the utility of combining them warrants further investigation. The study protocol was conducted following the amended F I G U R E 2 Kaplan-Meier curves according to clinical scenarios. Survival is shown up to 56 days to ensure better visualisation and scaling. Acute ⊕, high severity of acute disease was defined as a PaO 2 /FiO 2 ratio ≤200; Acute ⊖ absence of an acute condition; Chronic ⊕, high chronic disease burden was defined as an MCCI score ≥5; Chronic ⊖, absence of a chronic condition Patient consent was waived because of uncertainty of the risk of infection transmitted by fomites. Sebastián Chávez, Ariane Hernández and Dannette Guiñez; Formal analysis Clinical characteristics of coronavirus disease 2019 in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity Vascular mechanisms and manifestations of COVID-19 COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis COVID-19 in Latin America-emergency and opportunity SARS-CoV-2 positivity rate for Latinos in the Baltimore-Washington, DC Region COVID-19 situation update worldwide, as of 27 php?optio n= com_conte nt&view= a r t ic le&id=411&Itemi d=1183 ?id=10003 28&sec=5. Accessed Protocolo de Manejo Pacientes COVID-19 hospitalizados en sala Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19: endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA-secondary publication A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study Serial evaluation of the SOFA score to predict outcome in critically ill patients Assessment of clinical criteria for sepsis: for the third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) Nonlinear imputation of PaO 2 /FIO 2 from SpO 2 /FIO 2 among patients with acute respiratory distress syndrome Optimal target in septic shock resuscitation Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Covid-19 in critically ill patients in the Seattle region-case series Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxemic respiratory failure ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Dexamethasone in hospitalized patients with Covid-19-preliminary report Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis COVID-19 and VTE/anticoagulation: frequently asked questions Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries Risk prediction models for mortality in community-acquired pneumonia: a systematic review Additional Supporting Information may be found in the online version of the article at the publisher's website.